Cardinal Health Inc (NYSE: CAH) is set to report its fourth-quarter earnings before the opening bell on Tuesday, August 11, with analysts anticipating a significant rise in profitability and top-line growth. The Dublin, Ohio-based healthcare services company faces high expectations for earnings per share (EPS) of $2.42, up from $2.08 in the same quarter last year. Consensus estimates place quarterly revenue at $65.11 billion, a notable increase from the $60.16 billion reported in the year-ago period.

The earnings release comes shortly after Cardinal Health announced strategic acquisitions on July 20, signaling continued expansion in specialized care segments. The company plans to acquire the diabetes health business of Adapthealth and Strive Medical in its entirety for $360 million in cash. These moves aim to strengthen Cardinal Health’s position in chronic disease management and specialty pharmacy services.

Market sentiment remains cautiously optimistic ahead of the print. Shares of Cardinal Health rose 0.3% to close at $237.18 on Monday. However, analyst opinions vary, with several major firms adjusting their price targets in recent weeks. The divergence in ratings highlights differing views on the company’s near-term growth trajectory versus valuation concerns.

Analyst Ratings and Price Targets

Several prominent analysts have updated their outlooks for Cardinal Health stock recently. Most maintain positive ratings, citing strong operational performance, while others express caution.

The majority of recent adjustments reflect upward revisions, with UBS and TD Cowen leading the bullish sentiment by raising targets to $274 and $275 respectively. Both analysts boast accuracy rates of 71%, adding weight to their optimistic forecasts. Conversely, JP Morgan’s Lisa Gill cut her price target to $215 in May, maintaining a Neutral rating, which suggests some analysts see limited upside at current levels.

What the Numbers Show

The projected revenue jump from $60.16 billion to $65.11 billion represents a substantial year-over-year increase, indicating robust demand for Cardinal Health’s distribution and care solutions. Coupled with the EPS growth from $2.08 to $2.42, the data suggests improving operational efficiency or margin expansion. Investors will be watching closely to see if the $360 million acquisition spend impacts free cash flow or if it is funded through existing liquidity without diluting shareholder value. The disparity between the highest buy-side target ($275) and the neutral target ($215) underscores the market’s debate over whether the current valuation fully prices in this growth potential.

UBS analyst Kevin Caliendo has maintained a Buy rating on Cardinal Health and raised the price target to $274 from $260. The revision signals increased confidence in the company's near-term performance.

The new price target represents an upside from the previous level of $260. Cardinal Health trades on the NYSE under the ticker CAH.

Rating and Target Details